Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by bball67on Apr 21, 2022 1:46pm
140 Views
Post# 34621034

RE:RE:Argus opinion

RE:RE:Argus opinionFarmer, you sure are spreading alot of cow manure lately. Can we get you out of your grumpy mood. Is monkey testing better than testing "rats" (actually mice)? Lets say the nonhuman primate testing of PMN 310, in the April-June 2022 timeframe, produces some incredible therapeutic results. Lets say that dosing is tested from small dosages to 20X that dosage. Lets say that side effects at 20X are nil to minimal. Lets say we get the best possible results out of the monkey testing. Most of us will be estatic, and rightly so. How about you? Farmer, if you wait until the crop is ready, you miss the opportunity to add to your position. My guess is that you will completely downplay or write off any positive news from nonhuman primate testing. Tell me I am wrong. Would you be more convinced if we tested chickens or cattle?
<< Previous
Bullboard Posts
Next >>